低级别胶质瘤治疗早期成本与并发症数据表

基于大型国家数据库的低级别胶质瘤手术与活检的早期并发症和成本比较数据集。

NIAID Data Ecosystem
浏览 18
表格low-grade glioma (WHO grade II)costresectionstereotactic biopsyadverse events—complicationsMarketScan database
Datasheet1_Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.pdf

基本信息

模态
表格
大小
0.000732057 GB
许可
CC BY 4.0
创建/更新时间
2026-10-08
版本
v1

资源简介

低级别胶质瘤治疗早期成本与并发症数据表

【一句话概览】

本数据集是 figshare 公开的结构化表格数据集,收录 1 个文件、合计 732.06 KB,主题涵盖 low-grade glioma (WHO grade II)、cost、resection、stereotactic biopsy、adverse events—complications,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。

【数据集背景】

本数据集源站标题为《Datasheet1_Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.pdf》。配套论文《Contemporary management of low-­grade glioma: a paradigm shift in neuro-oncology》发表于 Practical Neurology(2017),DOI:10.1136/practneurol-2017-001604。源站首次发布:2023-02-03。

【数据内容】

源站原始描述:IntroductionDiffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13–16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have not been systematically evaluated. The purpose of this study was to better understand the complication rates and costs associated with each intervention. MethodsA retrospective cohort study using dat…

【数据结构与技术规格】

文件数 1 个,合计 732.06 KB。Datasheet1_Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.pdf:application/pdf,732.06 KB。数据集 DOI:10.3389/fsurg.2023.1001741.s001。

【主题与分类】

源站学科分类:Surgery、Oral and Maxillofacial Surgery、Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics)。主题标签:low-grade glioma (WHO grade II)、cost、resection、stereotactic biopsy、adverse events—complications、MarketScan database。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面:https://frontiersin.figshare.com/articles/dataset/Datasheet1_Early_costs_and_complications_of_first-line_low-grade_glioma_treatment_using_a_large_national_database_Limitations_and_future_perspectives_pdf/22002716

使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。

规范引用:Tuohy, Kyle; Ba, Djibril M.; Bhanja, Debarati; Leslie, Douglas; Liu, Guodong; Mansouri, Alireza (2023). Datasheet1_Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.pdf. Frontiers. Dataset

【使用注意】

· 源站最后修改于 2023-06-10,引用时请注意版本时效。

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付,我们提供全链路闭环服务,让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持?联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务(收技术服务费,非数据销售)

暂未开放

当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取(Figshare)

命令行下载

curl -L -o "Datasheet1_Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.pdf" "https://ndownloader.figshare.com/files/39052436"

文件清单

  • Datasheet1_Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives.pdf(732.06 KB)

文件总体积 732.06 KB(源站 API 实测)。

数据加载示例(图像类)

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

IntroductionDiffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13–16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have not been systematically evaluated. The purpose of this study was to better understand the complication rates and costs associated with each intervention.
MethodsA retrospective cohort study using data from the IBM Watson Health MarketScan® Commercial Claims and Encounters database was conducted, using the International Classification of Diseases, Ninth Revision (ICD-9) codes corresponding to DLGG (2005–2014). Current Procedure Terminology, 4th Edition (CPT-4) codes were used to differentiate resection and biopsy cohorts. Inverse weighting by the propensity score was used to balance baseline potential confounders (age, sex, pre-op seizure, geographic region, year, Charleston Comorbidity Index). Complication rates, hospital mortality, readmission, and costs were compared between groups.
ResultsWe identified 5,784 and 3,635 patients undergoing resection and biopsy, respectively, for initial DLGG management. Resection was associated with greater 30-day complications (29.17% vs. 26.34%; p Resection was not associated with an increase in the adjusted complication rate after balancing for baseline prognostic factors. Total costs and drug costs were higher with resection of DLGG, but the index procedure costs were higher for biopsy. This data should help to facilitate prospective health economic analyses in the future to understand the cost-effectiveness, and impact on quality of life, for DLGG interventions. However, the use of large national databases for studying long-term outcomes in DLGG management should be discouraged until there is greater specificity in the ICD coding system for DLGG subtypes.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fsurg.2023.1001741.s001(source: https://frontiersin.figshare.com/articles/dataset/Datasheet1_Early_costs_and_complications_of_first-line_low-grade_glioma_treatment_using_a_large_national_database_Limitations_and_future_perspectives_pdf/22002716)。

数据缺失?

依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。

⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。

获取专属数据定制方案